Why SQZ Biotechnologies Sank on Friday

1 min read

SQZ Biotechnologies (NYSE: SQZ) fell by nearly 16% on Friday following the company’s announcement of a new funding round.

SQZ (pronounced “squeeze”) is issuing 3 million new shares of common stock in an underwritten public offering that was priced Friday at $20 per share. This is below the company’s $22 per share closing price on Thursday.

As is customary in secondary stock flotations, SQZ’s underwriters have been granted a 30-day option to purchase extra stock. In this case, they can buy up to 450,000 shares.

Continue reading

Leave a Reply

Your email address will not be published.

Previous Story

Brixmor Property Group Inc (BRX) Q4 2020 Earnings Call Transcript

Next Story

Report: Facebook Developing Android-Based Smartwatch

Latest from Blog